| ANTIRETROVIRAL TREATMENTS (Part 1 of 7) |          |                     |          |  |  |  |
|---|----------|---------------------|----------|--|--|--|
| Generic                                 | Brand    | Strength            | Form     | Usual Dose   |  |  |
| CCR5 CO-RECEPT                          | OR ANTAG | GONISTS             |          |  |  |  |
| maraviroc (MVC)                         |          | 150mg, 300mg        | tabs     | Adults: $\geq 16yrs:$ Concomitant potent CYP3A inhibitors (eg, Pls<br>[except tipranavir/ritonavir], delavirdine, elvitegravir/ritonavir,<br>ketoconazole, itraconazole, clarithromycin, nefazodone,<br>telithromycin, boceprevir) (with or without a potent CYP3A<br>inducer): 150mg twice daily. Other concomitant drugs,<br>including tipranavir/ritonavir, nevirapine, raltegravir, NRTIs,<br>enfuviritde: 300mg twice daily. Concomitant potent CYP3A<br>inducers (eg, efavirenz, rifampin, etravirine, carbamazepine,<br>phenobarbital, phenytoin) (without a potent CYP3A inhibitor):<br>600mg twice daily. Severe renal dysfunction or ESRD (CrCI<br><30mL/min) (without potent CYP3A inhibitors):<br>fourg twice daily. Severe renal dysfunction or ESRD (CrCI<br><30mL/min) (without potent CYP3A inhibitors) inducers):<br>reduce dose from 300mg twice daily to 150mg twice daily if<br>postural hypotension occurs.<br><b>Children: &lt;2yrs: not established</b> . $\geq$ 2yrs: Concomitant potent<br>CYP3A inhibitors (eg, Pls [except tipranavir/ritonavir], delavirdine,<br>elvitegravir/ritonavir, ketoconazole, itraconazole, clarithromycin,<br>nefazodone, telithromycin, boceprevir) (with or without a potent<br>CYP3A inducer): (10–20kg): 50mg twice daily; (20–30kg):<br>75mg twice daily. (30–40kg): 100mg twice daily; (240kg):<br>150mg twice daily. Other concomitant drugs, including tipranavir/<br>ritonavir, nevirapine, raltegravir, NRTIs, enfuvirtide: (10–30kg):<br>not recommended; (30–40kg) or $\geq$ 40kg or $\geq$ 40kg): 300mg twice daily;<br>concomitant potent CYP3A inducers (eg, efavirenz, rifampin,<br>etravirine, carbamazepine, phenobarbital, phenytoin) (without a<br>potent CYP3A inhibitor): not recommended. |  |  |
| <b>FUSION INHIBITO</b>                  | RS       |                     |          | <u></u>  |  |  |
| enfuvirtide (ENF, T-20)                 | Fuzeon   | 90mg/mL             |          | Adults: ≥16yrs: 90mg twice daily via SC inj into upper arm,<br>anterior thigh, or abdomen<br>Children: <6yrs: not established. ≥6–16yrs: Limited data<br>available; recommended 2mg/kg (max 90mg) twice daily.   |  |  |
| <b>HIV-1 INTEGRASE</b>                  | STRAND   | TRANSFER IN         | HIBITORS |  |  |  |
| dolutegravir                            | Tivicay  | 10mg, 25mg,<br>50mg | tabs     | Adults: Treatment-naïve or treatment-experienced INSTI-naïve:<br>50mg once daily; when concomitant with certain UGT1A or<br>CYP3A inducers: 50mg twice daily. INSTI-experienced with<br>certain INSTI-associated resistance substitutions or clinically<br>suspected INSTI resistance: 50mg twice daily.<br>Children: <30kg or INSTI-experienced with documented<br>or clinically suspected resistance to other INSTIs<br>(raltegravir, elvitegravir): not established. Treatment-<br>naïve or treatment-experienced INSTI-naïve: (30– <40kg):<br>35mg once daily; (≥40kg): 50mg once daily, when<br>concomitant with certain UGT1A or CYP3A inducers:<br>increase weight-based dose to twice daily.   |  |  |
| elvitegravir                            | Vitekta  | 85mg, 150mg         | tabs     | Adults: 85mg once daily regimen: in combination with<br>atazanavir 300mg once daily + ritonavir 100mg once daily;<br>or with lopinavir 400mg twice daily + ritonavir 100mg<br>twice daily. 150mg once daily regimen: in combination with<br>darunavir 600mg twice daily + ritonavir 100mg twice daily; or<br>with fosamprenavir 700mg twice daily + ritonavir 100mg<br>twice daily; or with tipranavir 500mg twice daily + ritonavir<br>200mg twice daily. All regimens must be co-administered with<br>another antiretroviral agent.<br>Children: Not established.  |  |  |

| ANTIRETROVIRAL TREATMENTS (Part 2 of 7) |                |                        |                   |  |  |
|---|----------------|------------------------|-------------------|--|--|
| Generic                                 | Brand          | Strength               | Form              | Usual Dose   |  |
| <b>HIV-1 INTEGRASE</b>                  | E STRAND       | TRANSFER IN            | HIBITORS          | (continued)  |  |
| raltegravir potassium<br>(RAL)          | Isentress      | 25mg, 100mg+<br>400mg  | chew tabs<br>tabs | Adults: 400mg tab twice daily (avoid dosing prior to dialysis).<br>Concomitant rifampin: 800mg twice daily.<br>Children: <4wks: not established. ≥4wks (≥25kg):<br>one 400mg film-coated tab twice daily. If unable to swallow,<br>can use chew tabs: (25–<28kg): 150mg twice daily;<br>(28–<40kg): 200mg twice daily; ≥40kg: 300mg twice daily.<br>Chew tabs max dose: 300mg twice daily.   |  |
| NON-NUCLEOSID                           | DE REVERS      | E TRANSCRIP            | TASE INH          | IBITORS (NNRTIS)   |  |
| delavirdine mesylate<br>(DLV)           | Rescriptor     | 100mg, 200mg           | tabs              | Adults: ≥16yrs: 400mg 3 times daily.<br>Children: <16yrs: not established.   |  |
| efavirenz (EFV)                         | Sustiva        | 50mg, 200mg            | caps              | Adults and Children: Once daily on an empty stomach,   |  |
|   |                | 600mg                  | tabs              | preferably at bedtime. Consider pretreating with antihistamine<br>(for children) or steroid to minimize rash. <b>&lt;3mos or &lt;3.5kg:</b><br><b>not recommended</b> . ≥3mos: (3.5–<5kg): 100mg; (5–<7.5kg):<br>150mg; (7.5–<15kg): 200mg; (15–<20kg): 250mg;<br>(20–<25kg): 300mg; (25–<32.5kg): 350mg;<br>(32.5–<40kg): 400mg; (≥40kg) and adults: 600mg.<br>Concomitant voriconazole: increase voriconazole maintenance<br>dose to 400mg every 12hrs and decrease efavirenz dose to<br>300mg once daily using caps. Concomitant rifampin (≥50kg):<br>increase efavirenz dose to 800mg once daily.  |  |
| etravirine (ETR)                        | Intelence      | 25mg+, 100mg,<br>200mg | tabs              | Adults and Children: <6yrs or <16kg: not established.<br>Take twice daily after meals.<br>≥6-<18yrs: (≥16-<20kg): 100mg; (≥20-<25kg): 125mg;<br>(≥25-<30kg): 150mg; (≥30kg) or adults: 200mg.  |  |
| nevirapine (NVP)                        | Viramune       | 200mg+                 | tabs              | Adults: ≥16yrs: Initially 200mg once daily for 14 days; then   |  |
|   |                | 50mg/5mL               | oral susp         | 200mg twice daily.<br>Dialysis: Give additional 200mg after dialysis.<br>Children: <15days: not recommended.<br>≥15days: Initially 150mg/m <sup>2</sup> once daily for 14 days, then<br>increase to 150mg/m <sup>2</sup> twice daily.<br>Both: If mild-to-moderate rash occurs during the 14-day<br>lead in period, do not give twice-daily regimen until rash has<br>resolved. Max lead-in period: 28 days; consider alternative<br>regimen. If severe rash or hepatic event occurs, discontinue<br>permanently. Max 400mg/day. Retitrate if stopped for >7 days.   |  |
|   | Viramune<br>XR | 400mg                  | ext-rel tabs      | Adults: Initially Viramune 200mg once daily for 14 days, then Viramune XR 400mg once daily. If mild-to-moderate rash develops during the 14-day lead in period, do not start Viramune XR until rash has resolved. Lead-in period not necessary if patient already on a regimen of immediate-release Viramune twice daily. Max once-daily lead-in period: 28 days; consider alternative regimen. If severe rash or hepatic event occurs, discontinue permanently. Retitrate if stopped for >7 days. Children: <6yrs: not recommended. $\geq$ 6-<18yrs: Initially 150mg/m <sup>2</sup> Viramune oral susp or IR tabs once daily for 14 days (max 200mg/day); then Viramune XR dose based on BSA: 0.58–0.83m <sup>2</sup> : 200mg once daily. All: max 400mg/day. |  |
| rilpivirine                             | Edurant        | 25mg                   | tabs              | Adults and Children: <12yrs: not recommended.<br>≥12yrs (≥35kg): 25mg once daily with a meal.<br>Concomitant rifabutin: 50mg once daily; decrease to 25mg<br>once daily when rifabutin is stopped.   |  |

|  | ANTIRETROVIRAL TREATMENTS (Part 3 of 7)    |   |   |   |  |  |  |
|--|--|---|---|---|--|--|--|
| Generic  | Brand                                      |   | Form  | Usual Dose  |  |  |  |
| NUCLEOSIDE/NU  | CLEOTIDE                                   | REVERSE TRA   | ANSCRIPTA   | ASE INHIBITORS (NRTIS)  |  |  |  |
| abacavir sulfate<br>(ABC)  | Ziagen                                     | 300mg<br>20mg/mL  | tabs<br>oral soln <sup>1</sup>                            | Adults: >16yrs: 300mg twice daily or 600mg once daily. Mild<br>hepatic impairment: 200mg twice daily.<br>Children: <3mos: not established. $\geq$ 3mos (oral soln): 8mg/<br>kg twice daily or 16mg/kg once daily; max 600mg daily. If<br>able to swallow tabs: 14—<20kg: 300mg once daily or 150mg<br>twice daily; $\geq$ 20—<25kg: 450mg once daily or 150mg in the<br>AM and 300mg in the PM; $\geq$ 25kg: use Adult dose.  |  |  |  |
| abacavir sulfate<br>(ABC)/lamivudine<br>(3TC)                    | Epzicom                                    | ABC/3TC:<br>600mg/300mg                                     | tabs  | Adults: >18yrs: 1 tab daily. Hepatic or renal impairment<br>(CrCl <50mL/min): not recommended.<br>Children: ≤18yrs: not recommended.  |  |  |  |
| abacavir sulfate (ABC)/<br>lamivudine (3TC)/<br>zidovudine (ZDV) | Trizivir                                   | ABC/3TC/ZDV:<br>300mg/150mg/<br>300mg                       | tabs  | Adults: <40kg: not recommended. ≥40kg: 1 tab twice daily.<br>Children: Not recommended.   |  |  |  |
| didanosine (ddl)   | Videx EC                                   | 125mg, 200mg,<br>250mg, 400mg                               |   | Adults and Children: Take once daily on an empty stomach.<br><20kg: use oral soln. 20–<25kg: 200mg. 25–<60kg: 250mg.<br>≥60kg: 400mg. Renal impairment (CrCl 30–59mL/min):<br><60kg: 125mg. ≥60kg: 200mg. CrCl 10–29mL/min: 125mg.<br>CrCl <10mL/min or dialysis: <60kg: use oral soln; ≥60kg: 125mg.   |  |  |  |
|  | Videx<br>Pediatric<br>Pwd for<br>Oral Soln | 4g  | pediatric<br>pwd for oral<br>soln after<br>reconstitution | Adults: Take on an empty stomach. <60kg: 125mg twice daily<br>or 250mg once daily. ≥60kg: 200mg twice daily or 400mg once<br>daily. Renal impairment (CrCl 30–59mL/min): <60kg: 150mg<br>once daily or 75mg twice daily; ≥60kg: 200mg once daily or<br>100mg twice daily; CrCl 10–29mL/min: <60kg: 100mg once<br>daily; ≥60kg: 150mg once daily; CrCl <10mL/min or dialysis:<br><60kg: 75mg once daily; ≥60kg: 100mg once daily.<br>Children: <2wks: not recommended. 2wks–8mos:<br>100mg/m <sup>2</sup> twice daily. ≥8mos: 120mg/m <sup>2</sup> twice daily.<br>Renal impairment: Consider reducing dose and/or increasing<br>dosing interval. See full labeling. |  |  |  |
| emtricitabine (FTC)  | Emtriva                                    | 200mg   | caps  | Adults: ≥18yrs: 200mg once daily. Renal impairment<br>(CrCl 30–49mL/min): 200mg every 48hrs; (CrCl 15–29mL/<br>min): 200mg every 72hrs; (CrCl <15mL/min or dialysis):<br>200mg every 96hrs.<br>Children: <3mos: not recommended. 3mos–17yrs: ≤33kg:<br>Use soln form. >33kg: 200mg once daily.<br>Renal impairment: Reduce dose or prolong dosing interval.   |  |  |  |
|  |  | 10mg/mL   | oral soln   | Adults: ≥18yrs: 240mg once daily. Renal impairment:<br>(CrCl 30–49mL/min): 120mg once daily; (CrCl 15–29mL/min):<br>80mg once daily; (CrCl <15mL/min): 60mg once daily.<br>Children: <3mos: 3mg/kg once daily. 3mos–17yrs:<br>6mg/kg once daily; max 240mg/day. >33kg: May use cap form.<br>Renal impairment: Reduce dose or prolong dosing interval.   |  |  |  |
| emtricitabine (FTC)/<br>tenofovir disoproxil<br>fumarate (TDF)   | Truvada                                    | 100mg/150mg,<br>133mg/200mg,<br>167mg/250mg,<br>200mg/300mg | tabs  | Adults: ≥35kg: 200mg/300mg once daily.<br>Renal impairment: CrCl 30–49mL/min: 200mg/300mg every<br>48hrs; CrCl <30mL/min, hemodialysis: not recommended.<br>Children: <17kg: not established.<br>17–<22kg: 100mg/150mg once daily. 22–<28kg:<br>133mg/200mg once daily. 28–<35kg: 167mg/250mg once<br>daily. ≥35kg: 200mg/300mg once daily.   |  |  |  |

| ANTIRETROVIRAL TREATMENTS (Part 4 of 7) |          |   |  |  |  |
|---|----------|---|--|--|--|
| Generic                                 | Brand    | Strength                                | Form   | Usual Dose   |  |
| NUCLEOSIDE/NU                           | CLEOTIDE | <b>REVERSE TR</b>                       | ANSCRIPTA  | SE INHIBITORS (NRTIS) (continued)  |  |
| lamivudine (3TC)                        | Epivir   | 150mg+,<br>300mg<br>10mg/mL             | tabs<br>oral soln                                    | Adults: CrCl ≥50mL/min: 300mg once daily or 150mg<br>twice daily; CrCl 30–49mL/min: 150mg once daily; CrCl<br>15–29mL/min: 150mg for 1st dose then 100mg once daily;<br>CrCl 5–14mL/min: 150mg for 1st dose then 50mg once daily;<br>CrCl 45mL/min: 50mg for 1st dose then 25mg once daily;<br><b>Children: &lt;3mos: not established.</b> ≥3mos (oral soln):<br>4mg/kg twice daily or 8mg/kg once daily; max 300mg/day.<br>Tabs: 14–<20kg: 150mg once daily or 75mg twice daily;<br>≥20–<25kg: 225mg once daily or 75mg in the AM and<br>150mg in the PM; ≥25kg: 300mg once daily or 150mg<br>twice daily. Renal impairment: reduce dose or prolong<br>dosing interval. |  |
| lamivudine (3TC)/<br>zidovudine (ZDV)   | Combivir | 3TC/ZDV:<br>150mg/300mg                 | tabs   | Adults: 1 tab twice daily. Hepatic or renal impairment<br>(CrCl <50mL/min): not recommended.<br>Children: Not recommended.   |  |
| stavudine (d4T)                         | Zerit    | 15mg, 20mg,<br>30mg, 40mg<br>1mg/mL     | caps<br>pwd for oral<br>soln after<br>reconstitution | Adults: ≥60kg: 40mg every 12hrs; <60kg: 30mg every<br>12hrs.<br>Renal impairment: ≥60kg (CrCl 26–50mL/min): 20mg every<br>12hrs; (CrCl 10–25mL/min), dialysis: 20mg every 24hrs.<br><60kg (CrCl 26–50mL/min): 15mg every 12hrs;<br>(CrCl 10–25mL/min), dialysis: 15mg every 24hrs.<br>Children: ≤13 days: 0.5mg/kg every 12hrs. ≥14 days:<br>(<30kg): 1mg/kg every 12hrs. ≥30kg: as adult.<br>Renal impairment: Reduce dose or increase dosing interval.   |  |
| tenofovir disoproxil<br>fumarate (TDF)  | Viread   | 150mg, 200mg,<br>250mg, 300mg<br>40mg/g | tabs<br>oral pwd                                     | Adults: ≥12yrs (≥35kg): 300mg once daily. Renal impairment:<br>CrCl 30–49mL/min: 300mg every 48hrs; CrCl 10–29mL/min:<br>300mg every 72–96hrs; hemodialysis: 300mg every 7 days<br>or after a total of 12hrs of dialysis; CrCl <10mL/min: not<br>recommended.<br>Children: <2yrs: Not established. ≥2yrs: 8mg/kg once daily;<br>max 300mg/day. ≥17kg: may use tabs if able to swallow.<br>17–<22kg: 150mg once daily. 22–<28kg: 200mg once daily. 28–<br>35kg: 250mg once daily. ≥35kg: 300mg once daily. See<br>full labeling for additional dosing based on body wt.   |  |
| zidovudine (ZDV)                        | Retrovir | 100mg<br>300mg<br>50mg/5mL<br>10mg/mL   |  | Adults: ≥18yrs: 600mg daily in divided doses.   End-stage renal disease on dialysis: 100mg every 6–8hrs.   Vertical transmission, severe anemia and/or neutropenia:   See full labeling.   Children: <6wks and/or for vertical transmission: See full labeling.  |  |
|   |          |   |  | can be given. 1mg/kg 5–6 times daily. End-stage renal disease<br>on dialysis: 1mg/kg every 6–8hrs. Vertical transmission, severe<br>anemia and/or neutropenia: See full labeling.<br><b>Children:</b> Vertical transmission: See full labeling.  |  |

| ANTIRETROVIRAL TREATMENTS (Part 5 of 7) |            |  |                               |  |  |  |
|---|------------|--|-------------------------------|--|--|--|
| Generic                                 | Brand      | :  | Form                          | Usual Dose   |  |  |
| PHARMACOKINE                            | TIC ENHAI  | NCER                                     |                               |  |  |  |
| cobicistat                              |            | 150mg                                    | tabs                          | Adults: Must be co-administered at same time as atazanavir<br>or darunavir. ≥18yrs: 150mg once daily with atazanavir 300mg<br>once daily (if treatment-naive or experienced) or with darunavir<br>800mg once daily (if treatment-naive or experienced with no<br>darunavir resistance associated substitutions).<br>Children: <18yrs: not established.   |  |  |
| <b>PROTEASE INHIB</b>                   | ITORS (PIS | 3)                                       |                               |  |  |  |
| atazanavir sulfate<br>(ATV)             | Reyataz    | 150mg,<br>200mg, 300mg<br>50mg           | caps<br>oral pwd <sup>3</sup> | Adults: Take with food. <i>Treatment-naive</i> : atazanavir 300mg<br>+ ritonavir 100mg once daily; atazanavir 400mg once daily if<br>unable to tolerate ritonavir; concomitant efavirenz: atazanavir<br>400mg + ritonavir 100mg once daily + efavirenz 600mg at<br>bedtime (on an empty stomach); ESRD with hemodialysis:<br>atazanavir 300mg + ritonavir 100mg; hepatic impairment:<br>(mild): 400mg once daily; (moderate): 300mg once daily;<br>(severe): not recommended. <i>Treatment-experienced</i> :<br>atazanavir 300mg + ritonavir 100mg once daily; concomitant<br>Hy-blocker and tenofovir: atazanavir 400mg + ritonavir<br>100mg once daily. <i>Concomitant tenofovir</i> : atazanavir 300mg<br>+ tenofovir 300mg + ritonavir 100mg once daily.<br><i>Pregnancy</i> : atazanavir 300mg + ritonavir 100mg once daily.<br><i>Concomitant</i> H <sub>2</sub> -blocker or tenofovir (2nd or 3rd trimester):<br>atazanavir 400mg + ritonavir 100mg. See full labeling.<br><b>Children:</b> < <b>6yrs: not recommended</b> . Take with food. Take<br>once daily. 6−18yrs: 15−<20kg: atazanavir 100mg, <i>Teatment-<br/>naive</i> : ≥13yrs and ≥40kg who are unable to tolerate ritonavir:<br>atazanavir 400mg once daily. Patients ≥13yrs and ≥40kg<br>receiving concomitant tenofovir, Hy-blockers, or PIs: take   |  |  |
| darunavir ethanolate<br>(DRV)           | Prezista   | 75mg, 150mg,<br>600mg, 800mg<br>100mg/mL | tabs<br>oral susp             | atazanavir with ritonavir. See full labeling.<br>Adults: >18yrs: Treatment-naive or treatment-experienced<br>with no darunavir resistance associated substitutions:<br>darunavir 800mg + ritonavir 100mg once daily. Treatment-<br>experienced with at least one darunavir resistance associated<br>substitution or with no baseline resistance information:<br>darunavir 600mg + ritonavir 100mg twice daily. Pregnancy:<br>darunavir 600mg + ritonavir 100mg twice daily. Pregnancy:<br>darunavir 600mg + ritonavir 100mg twice daily. Pregnancy:<br>darunavir 600mg + ritonavir 100mg once daily only if stable<br>on dose prior to pregnancy and virologically suppressed (HIV-<br>1 RNA <50copies/ml).<br>Children: <3yrs: not recommended. Treatment-naive<br>or treatment-experienced with no darunavir resistance<br>associated substitutions: >3yrs to <18yrs:<br>>10kg-<11kg: darunavir 350mg + ritonavir 64mg once daily;<br>>11kg-<12kg: darunavir 420mg + ritonavir 80mg once daily;<br>>11kg-<13kg: darunavir 420mg + ritonavir 80mg once daily;<br>>13kg-<14kg: darunavir 40mg + ritonavir 80mg once daily;<br>>14kg-<15kg: darunavir 675mg + ritonavir 100mg once daily;<br>>40kg: darunavir 800mg + ritonavir 100mg once daily;<br>>11kg-<12kg: darunavir 200mg + ritonavir 32mg twice daily;<br>>11kg-<12kg: darunavir 200mg + ritonavir 40mg twice daily;<br>>11kg-<13kg: darunavir 200mg + ritonavir 40mg twice daily;<br>>11kg-<13kg: darunavir 200mg + ritonavir 40mg twice daily;<br>>11kg-<13kg: darunavir 200mg + ritonavir 40mg twice daily;<br>>11kg-<14kg: darunavir 200mg + ritonavir 40mg twice daily;<br>>11kg-<14kg: darunavir 200mg + ritonavir 40mg twice daily;<br>>12kg-<14kg: darunavir 200mg + ritonavir 40mg twice daily;<br>>14kg-<15kg: darunavir 200mg + ritonavir 40mg twice daily;<br>>15kg-<14kg: darunavir 200mg + ritonavir 40mg twice daily;<br>>15kg-<14kg: darunavir 200mg + ritonavir 40m |  |  |

| ANTIRETROVIRAL TREATMENTS (Part 6 of 7) |          |  |   |  |  |  |  |
|---|----------|--|---|--|--|--|--|
| Generic                                 | Brand    | Strength   | Form  | Usual Dose   |  |  |  |
| PROTEASE INHIBITORS (PIS) (continued)   |          |  |   |  |  |  |  |
| fosamprenavir<br>calcium (FOS-APV)      | Lexiva   | 700mg<br>50mg/mL   | tabs<br>oral susp   | Adults: Oral susp: take without food. Therapy-naive: 1.4g<br>twice daily; or fosamprenavir 1.4g + ritonavir 200mg once<br>daily; or fosamprenavir 1.4g + ritonavir 100mg once daily; or<br>fosamprenavir 700mg + ritonavir 100mg twice daily.<br>Pl-experienced: fosamprenavir 700mg + ritonavir 100mg<br>twice daily. Hepatic dysfunction: See full labeling.<br><b>Children: Pl-naive (&lt;4wks) or Pl-experienced (&lt;6mos):</b><br><b>not recommended</b> . Oral susp: Take twice daily with food.<br>Pl-naive (≥4wks–18yrs) or Pl-experienced (≥6mos): <11kg:<br>losamprenavir 45mg/kg + ritonavir 7mg/kg;<br>11—<15kg: fosamprenavir 30mg/kg + ritonavir 3mg/kg;<br>≥20kg: fosamprenavir 30mg/kg + ritonavir 3mg/kg.<br>Pl-naive (≥2yrs): fosamprenavir 30mg/kg.<br><b>Both:</b> If emesis occurs within 30min after dosing, re-dose. Do<br>not exceed adult dose. See full labeling.   |  |  |  |
| indinavir sulfate (IDV)                 | Crixivan | 200mg, 400mg   | caps  | Adults: Take with water on an empty stomach or with a light<br>meal. 800mg every 8hrs. Concomitant rifabutin: 1g every 8hrs<br>and reduce rifabutin dose by ½.<br>Concomitant ketoconazole, itraconazole, delavirdine, or<br>hepatic insufficiency: 600mg every 8hrs.<br>Children: Not established. 3–18yrs: 500mg/m <sup>2</sup> every 8hrs<br>has been used; see full labeling.  |  |  |  |
| lopinavir (LPV)/<br>ritonavir (RTV)     | Kaletra  | LPV/RTV:<br>100mg/25mg,<br>200mg/50mg<br>LPV/RTV:<br>80mg/20mg<br>per mL | tabs<br>oral soln <sup>2,5</sup>                                | Adults: Oral soln: take with food. ≥18yrs: <3 lopinavir<br>resistance-associated substitutions: 400/100mg twice daily<br>or 800/200mg once daily. ≥3 lopinavir resistance-associated<br>substitutions or concomitant carbamazepine, phenobarbital,<br>phenytoin, efavirenz, nevirapine, nelfinavir, or if pregnant (avoid<br>oral soln): once-daily dosing not recommended. Concomitant<br>efavirenz, nevirapine, or nelfinavir: 500/125mg (two 200/50mg<br>tabs + one 100/25mg tab) or 520/130mg (6.5mL) twice daily.<br><b>Children:</b> <42wks postmenstrual age or <14 days<br>postnatal: not recommended. 14days–6mos: 16/4mg/kg<br>or 300/75mg/m <sup>2</sup> twice daily. Do not administer with efavirenz,<br>nevirapine, or nelfinavir. >6mos–<18yrs: 230/57.5mg/m <sup>2</sup><br>twice daily, or if <15kg: 12/3mg/kg twice daily; ≥15–40kg:<br>10/2.5mg/kg twice daily; >40kg: max 400/100mg twice daily.<br>Concomitant efavirenz, nevirapine, or nelfinavir:>6mos–<18yrs:<br>300/75mg/m <sup>2</sup> twice daily, or if <15kg: 13/3.25mg/kg twice<br>daily; s15–45kg: 11/2.75mg/kg twice daily; >45kg: max<br>oral soln: 520/130mg (6.5mL) twice daily, or max tabs:<br>500/125mg twice daily. See full labeling. |  |  |  |
| nelfinavir mesylate<br>(NFV)            | Viracept | 250mg, 625mg<br>50mg/g   | tabs<br>oral pwd <sup>3</sup>                                   | Adults and Children: Take with food.<br><2yrs: not recommended. 2–13yrs: 45–55mg/kg twice<br>daily or 25–35mg/kg 3 times daily; max 2.5g/day. >13yrs:<br>1.25g twice daily or 750mg 3 times daily. Reduce concomitant<br>rifabutin dose by ½ and give nelfinavir 1.25g twice daily.  |  |  |  |
| ritonavir (RTV)                         | Norvir   | 100mg<br>80mg/mL   | tabs, soft<br>gel caps <sup>2,5</sup><br>oral soln <sup>2</sup> | Adults: Take with meals. Initially at least 300mg twice daily,<br>increase every 2–3 days by 100mg twice daily to 600mg<br>twice daily. Concomitant other PIs (eg, atazanavir, darunavir,<br>fosamprenavir, saquinavir, tipranavir): Reduce ritonavir dose.<br>See full labeling.<br>Children: <1mo or before postmenstrual age<br><44wks: not recommended. >1mo: Initially 250mg/m <sup>2</sup><br>twice daily; increase every 2–3 days by 50mg/m <sup>2</sup> twice daily<br>to 350–400mg/m <sup>2</sup> twice daily, max 600mg twice daily.   |  |  |  |

| ANTIRETROVIRAL TREATMENTS (Part 7 of 7)  |            |                             |   |   |  |
|--|------------|-----------------------------|---|---|--|
| Generic  | Brand      | Strength                    | Form  | Usual Dose  |  |
| PROTEASE INHIB   | ITORS (PIS | ) (continued)               |   |   |  |
| saquinavir mesylate<br>(SQV)   | Invirase   | 500mg<br>200mg              | tabs<br>hard gel caps                                   | Adults: Take within 2hrs after a meal. ≥16yrs: saquinavir<br>1g twice daily + ritonavir 100mg twice daily (taken at same<br>time). Treatment-naive or switching from a delavirdine- or<br>rilpivirine-containing regimen: initially saquinavir 500mg twice<br>daily + ritonavir 100mg twice daily for 7 days, then increase<br>to saquinavir 1g twice daily + ritonavir 100mg twice daily.<br>Children: <16yrs: not recommended.  |  |
| tipranavir (TPV)   | Aptivus    | 250mg<br>100mg/mL           | soft gel<br>caps <sup>2</sup><br>oral soln <sup>4</sup> | Adults: Tipranavir 500mg + ritonavir 200mg twice daily.<br>Children: <2yrs: not recommended. Use oral soln if unable<br>to swallow caps. 2–18yrs: tipranavir 14mg/kg + ritonavir<br>6mg/kg or (375mg/m <sup>2</sup> + ritonavir 150mg/m <sup>2</sup> ) twice daily;<br>max tipranavir 500mg + ritonavir 200mg twice daily.<br>Intolerance or toxicity (if virus not resistant to multiple PIs):<br>may reduce dose to tipranavir 12mg/kg + ritonavir 5mg/kg or<br>(290mg/m <sup>2</sup> + ritonavir 115mg/m <sup>2</sup> ) twice daily. |  |
| MULTICLASS FIXE  | ED-DOSE C  | COMBINATIO                  | N   |   |  |
| abacavir/<br>dolutegravir/<br>lamivudine)  | Triumeq    | 600mg/50mg/<br>300mg        | tabs  | Adults: 1 tab daily. Concomitant efavirenz, fosamprenavir/<br>ritonavir, tipranavir/ritonavir, rifampin/carbamazepine: give<br>additional dolutegravir 50mg separated by 12hrs from Triumeq.<br>Children: Not established.  |  |
| atazanavir/cobicistat  | LIGUL      | 300mg/150mg                 | tabs  | Adults: 1 tab daily.<br>Children: <18yrs: not established.  |  |
| darunavir/cobicistat   |            | 800mg/150mg                 | tabs  | Adults: 1 tab daily.<br>Children: <18yrs: not established.  |  |
| efavirenz (EVF)/<br>emtricitabine (FTC)/<br>tenofovir disoproxil<br>fumarate (TDF)         | Atripla    | 600mg/200mg/<br>300mg       | tabs  | Adults: ≥12yrs and ≥40kg: 1 tab once daily preferably at   bedtime. Concomitant rifampin (≥50kg): Give additional   200mg/day of efavirenz.   Children: <12yrs: not recommended.  |  |
| emtricitabine (FTC)/<br>rilpivirine/tenofovir<br>alafenamide (TAF)                         | Odefsey    | 200mg/25mg/<br>25mg         | tabs  | Adults & Children: <12yrs (<35kg): not established.<br>≥12yrs (≥35kg): 1 tab once daily with food. Severe renal<br>impairment (CrCl <30mL/min): not recommended.  |  |
| emtricitabine (FTC)/<br>rilpivirine/tenofovir<br>disoproxil fumarate<br>(TDF)              | Complera   | 200mg/25mg/<br>300mg        | tabs  | Adults: ≥12yrs (and ≥35kg): 1 tab once daily with a meal.<br>Renal impairment (CrCl<50mL/min): not recommended.<br>Concomitant rifabutin: take additional rilpivirine 25mg<br>once daily.<br>Children: <12yrs or <35kg: not established.  |  |
| emtricitabine<br>(FTC)/tenofovir<br>alafenamide (TAF)                                      | Descovy    | 200mg/25mg                  | tabs  | Adults & Children: <12yrs (<35kg): not established.<br>≥12yrs (≥35kg): 1 tab once daily. Severe renal impairment<br>(CrCl <30mL/min): not recommended.  |  |
| elvitegravir/cobicistat/<br>emtricitabine (FTC)/<br>tenofovir alafenamide<br>(TAF)         |            | 150mg/150mg/<br>200mg/10mg  |   | Adults and Children: <12yrs: not established.<br>≥12yrs and ≥35kg: 1 tab once daily with food. Severe hepatic<br>or renal impairment (CrCl <30mL/min): not recommended.   |  |
| elvitegravir/cobicistat/<br>emtricitabine (FTC)/<br>tenofovir disoproxil<br>fumarate (TDF) | Stribild   | 150mg/150mg/<br>200mg/300mg | tabs  | Adults and Children: <12yrs or <35kg: not established.<br>≥12yrs (≥35kg): 1 tab once daily with food. Renal impairment<br>(CrCl <70mL/min): not recommended; discontinue if CrCl<br>declines to <50mL/min during therapy; also in children: no<br>data available. Severe hepatic impairment: not recommended.   |  |
| NOTES  |            |                             |   |   |  |

Key: + = scored; PI = protease inhibitor <sup>1</sup>Contains parabens, propylene glycol; <sup>2</sup>Contains alcohol; <sup>3</sup>Contains phenylalanine; <sup>4</sup>Contains Vit. E 116 IU/mL; <sup>5</sup>Keep in refrigerator (Rev. 5/2017)